Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.48 |
| ▸ | ALPL | P05186 | 3/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558721 | 0.93 | SLC16A3 (0.51) | IDH1SLC22A12ALPLPTK2BFABP4 | |
| SCHEMBL3556453 | 0.91 | RXRA (0.53) | IDH1RXRARXRBRXRGSLC22A12 | |
| SCHEMBL3554994 | 0.90 | SLC16A3 (0.50) | IDH1SLC22A12ALPLPTK2BFABP4 | |
| SCHEMBL3561309 | 0.86 | FABP4 (0.48) | IDH1SLC22A12ALPLFABP4FABP5 | |
| SCHEMBL3562430 | 0.84 | IDH1 (0.53) | IDH1RXRASLC22A12PTK2BSLC16A3 | |
| SCHEMBL3563292 | 0.83 | PTK2B (0.58) | IDH1PTK2BFABP4HSD17B1HSD17B2 | |
| SCHEMBL3557532 | 0.82 | SERPINE1 (0.51) | SLC16A3 | |
| SCHEMBL3560779 | 0.82 | SLC16A3 (0.64) | RXRARXRBRXRGALPLSLC16A3 | |
| SCHEMBL3563150 | 0.80 | SLC16A3 (0.68) | SLC22A12ALPLPTK2BSLC16A3 | |
| SCHEMBL3558846 | 0.80 | TSHR (0.70) | FABP4FABP5SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | IDH1 970/4885RXRA 1293/4885RXRB 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.